Literature DB >> 24837879

Coating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against Leishmania in hamsters by inducing Th1-type immune responses.

S Kansal1, R Tandon, A Verma, P Misra, A K Choudhary, R Verma, P R P Verma, A Dube, P R Mishra.   

Abstract

BACKGROUND AND
PURPOSE: The aim of the present study was to evaluate the immunomodulatory and chemotherapeutic potential of alginate-(SA) coated nanocapsule (NCs) loaded with doxorubicin (SA-NCs-DOX) against visceral leishmaniasis in comparison with nano-emulsions containing doxorubicin (NE-DOX). EXPERIMENTAL APPROACH: NE-DOX was prepared using low-energy emulsification methods. Stepwise addition of protamine sulphate and SA in a layer-by-layer manner was used to form SA-NCs-DOX. SA-NCs-DOX, NE-DOX and Free DOX were compared for their cytotoxicity against Leishmania donovani-infected macrophages in vitro and generation of T-cell responses in infected hamsters in vivo. KEY
RESULTS: Size and ζ potential of the NE-DOX and SA-NCs-DOX formulations were 310 ± 2.1 nm and (-)32.6 ± 2.1 mV, 342 ± 4.1 nm and (-)29.3 ± 1.2 mV respectively. SA-NCs-DOX was better (1.5 times) taken up by J774A.1 macrophages compared with NE-DOX. SA-NCs -DOX showed greater efficacy than NE-DOX against intramacrophagic amastigotes. SA-NCs-DOX treatment exhibited enhanced apoptotic efficiency than NE-DOX and free DOX as evident by cell cycle analysis, decrease in mitochondrial membrane potential, ROS and NO production. T-cell responses, when assessed through lymphoproliferative responses, NO production along with enhanced levels of iNOS, TNF-α, IFN-γ and IL-12 were found to be up-regulated after SA-NCs-DOX, compared with responses to NE-DOX in vivo. Parasitic burden was decreased in Leishmania-infected hamsters treated with SA-NCs-DOX, compared with NE-DOX. CONCLUSIONS AND IMPLICATIONS: Our results provide insights into the development of an alternative approach to improved management of leishmaniasis through a combination of chemotherapy with stimulation of the innate immune system.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24837879      PMCID: PMC4243977          DOI: 10.1111/bph.12754

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  54 in total

1.  Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis.

Authors:  Shaswat Kansal; Rati Tandon; Pankaj Dwivedi; Pragya Misra; P R P Verma; Anuradha Dube; Prabhat Ranjan Mishra
Journal:  J Antimicrob Chemother       Date:  2012-08-07       Impact factor: 5.790

2.  Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide.

Authors:  F Y Liew; Y Li; S Millott
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

3.  Potential of doxorubicin as an antileishmanial agent.

Authors:  R Sett; N Basu; A K Ghosh; P K Das
Journal:  J Parasitol       Date:  1992-04       Impact factor: 1.276

4.  Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.

Authors:  Reema Gupta; Pramod K Kushawaha; Mukesh Samant; Anil K Jaiswal; Rajendra K Baharia; Anuradha Dube
Journal:  J Antimicrob Chemother       Date:  2011-11-25       Impact factor: 5.790

5.  Stimulation of various functions in murine peritoneal macrophages by high mannuronic acid-containing alginate (HMA) exposure in vivo.

Authors:  E H Son; E Y Moon; D K Rhee; S Pyo
Journal:  Int Immunopharmacol       Date:  2001-01       Impact factor: 4.932

6.  Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?

Authors:  L Thiele; B Rothen-Rutishauser; S Jilek; H Wunderli-Allenspach; H P Merkle; E Walter
Journal:  J Control Release       Date:  2001-09-11       Impact factor: 9.776

7.  Interleukin 10 production correlates with pathology in human Leishmania donovani infections.

Authors:  H W Ghalib; M R Piuvezam; Y A Skeiky; M Siddig; F A Hashim; A M el-Hassan; D M Russo; S G Reed
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Cell-cycle-dependent translation of histone mRNAs is the key control point for regulation of histone biosynthesis in Leishmania infantum.

Authors:  Manuel Soto; Salvador Iborra; Luis Quijada; Cristina Folgueira; Carlos Alonso; Jose M Requena
Journal:  Biochem J       Date:  2004-05-01       Impact factor: 3.857

9.  Potential role of nuclear factor-kappaB in the induction of nitric oxide and tumor necrosis factor-alpha by oligochitosan in macrophages.

Authors:  Zhijun Yu; Luhang Zhao; Haiping Ke
Journal:  Int Immunopharmacol       Date:  2004-02       Impact factor: 4.932

10.  Use of antimony in the treatment of leishmaniasis: current status and future directions.

Authors:  Arun Kumar Haldar; Pradip Sen; Syamal Roy
Journal:  Mol Biol Int       Date:  2011-06-08
View more
  4 in total

1.  Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis.

Authors:  Pramod K Gupta; Anil K Jaiswal; Shalini Asthana; Ashwni Verma; Vivek Kumar; Prashant Shukla; Pankaj Dwivedi; Anuradha Dube; Prabhat R Mishra
Journal:  Pharm Res       Date:  2014-11-26       Impact factor: 4.200

Review 2.  Nanostructured delivery systems with improved leishmanicidal activity: a critical review.

Authors:  Natascia Bruni; Barbara Stella; Leonardo Giraudo; Carlo Della Pepa; Daniela Gastaldi; Franco Dosio
Journal:  Int J Nanomedicine       Date:  2017-07-26

3.  Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis.

Authors:  Maiara Maria Romanelli; Thais Alves da Costa-Silva; Edezio Cunha-Junior; Daiane Dias Ferreira; Juliana M Guerra; Andres Jimenez Galisteo; Erika Gracielle Pinto; Leandro R S Barbosa; Eduardo Caio Torres-Santos; Andre Gustavo Tempone
Journal:  Front Cell Infect Microbiol       Date:  2019-10-29       Impact factor: 5.293

4.  Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment.

Authors:  Bo Deng; Bing Ma; Yingying Ma; Pei Cao; Xigang Leng; Pengyu Huang; Yuanyuan Zhao; Tianjiao Ji; Xueguang Lu; Lanxia Liu
Journal:  J Nanobiotechnology       Date:  2022-03-18       Impact factor: 10.435

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.